|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
100 项与 Orum Therapeutics USA, Inc. 相关的临床结果
0 项与 Orum Therapeutics USA, Inc. 相关的专利(医药)
100 项与 Orum Therapeutics USA, Inc. 相关的药物交易
100 项与 Orum Therapeutics USA, Inc. 相关的转化医学